P2RY6+ tumor-associated macrophages as a therapeutic target: suppressing tumor growth and enhancing chemosensitivity in triple-negative breast cancer
Xin Wang, Mingyue Ma, Mingyu Zhang, Han Lu, Ying Liu, Yang Zhou, Bing Han · 2026
Read P2RY6+ tumor-associated macrophages as a therapeutic target: suppressing tumor growth and enhancing chemosensitivity in triple-negative breast cancer by Xin Wang, Mingyue Ma, Mingyu Zhang, Han Lu, Ying Liu, Yang Zhou, Bing Han (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473056.txt.
Description
Wang and co-authors fingered a receptor on tumor-associated macrophages, the immune cells that shield triple-negative breast cancer, as a drug target. Their 2026 study combined single-cell data, tissue arrays from 29 surgical patients, and mouse tumor models to trace how the UDP-sensing receptor P2RY6 steers macrophages into tumor-helping mode.
Activated P2RY6 pushed macrophages toward the M2-like state through a calcium signaling chain. It made them secrete S100A9, a protein that switches on NF-κB growth signaling in the cancer cells themselves. Tumors dense in P2RY6-positive macrophages carried a poor prognosis for patients. Blocking the receptor, genetically or with drugs, or neutralizing S100A9 slowed tumor growth in mice and restored sensitivity to chemotherapy, the team reports.
Catalog record
| CREATOR | Xin Wang, Mingyue Ma, Mingyu Zhang, Han Lu, Ying Liu, Yang Zhou, Bing Han |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |